SPECTRAL INC
Medical

FDA ACCEPTS SPECTRAL'S PMA FOR TORAYMYXIN ™ FOR REVIEW

Toronto, Canada – July 24, 2017 – Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock, today announced that the United States Food and Drug Administration ("FDA") has accepted its rolling PMA application for Toraymyxin™ ("PMX") for review.

The acceptance of the filing means that the FDA has made a threshold determination that the application is sufficiently complete to permit a substantive review. The Company will continue to work closely with the FDA to facilitate a timely process.

"The acceptance of this PMA filing for review by the FDA represents another significant step forward in our regulatory pathway towards potential approval of our personalized treatment for patients with endotoxemic septic shock. The incidence of sepsis continues to rise in North America with no specific treatment yet available," said Dr. Paul Walker, President and CEO of Spectral.

About Spectral

Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ ('PMX"). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.

PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 150,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 350,000 patients are diagnosed with severe sepsis and septic shock in North America each year. Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit www.spectraldx.com

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future

outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

For further information, please contact:

Anthony Businskas

Executive Vice President and CFO
Spectral Medical Inc.
416-626-3233 ext. 2200

tbusinskas@spectraldx.com

Ali Mahdavi

Capital Markets & Investor Relations

416-962-3300

am@spinnakercmi.com